A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
Entospletinib is an investigational drug designed to inhibit the growth of blood cancers by blocking the activity of an enzyme called Syk, which can fuel the growth of these cancers. In this study, investigators are evaluating the safety of and finding the optimal dose of entospletinib to give with vincristine and dexamethasone in patients with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued growing despite prior therapy. Entospletinib and dexamethasone are taken orally (by mouth), while vincristine is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have recurrent or persistent B-cell ALL despite previous treatment.
- Patients should recover from the serious side effects of prior therapies before entering the study.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Jae Park at 212-639-4048.